Logo
PURI COLL Rh Recombinant Human Collagen Booster

PURI COLL Rh Recombinant Human Collagen Booster

Aeterderm

Injectable skin booster
  • Manufactured in South Korea under controlled laboratory and factory conditions using recombinant DNA technology.
  • Animal Free collagen source, supporting ethical and regulatory preferences over animal Derived collagen.
  • Marketed as a medical device/skin booster in many aesthetic markets; local regulatory classification and approvals vary by country and should be confirmed before use.
  • Produced by WEDERM, an OEM/medical aesthetics manufacturer with international export markets (e.g. Brazil, Kazakhstan, Thailand, UAE), indicating compliance with relevant export and quality standards in those regions.
Recombinant human collagen biostimulator / skin rejuvenation injectable

Description

PURI COLL Rh is a next-generation injectable skin booster based on 100% human-identical recombinant collagen Types I and III, engineered via recombinant DNA expression vector technology. The product combines recombinant human collagen (7.5 mg Type I + 7.5 mg Type III) with hyaluronic acid, PDRN (polynucleotide), succinic acid and multi-peptides to deliver both immediate structural support and long-term dermal regeneration. Because the collagen genome is 100% identical to endogenous human collagen, PURI COLL Rh offers high biocompatibility with minimal risk of immune rejection, rapid integration into tissue and an extended molecular lifespan. Clinically, it provides superior cell activity compared with animal-derived collagen, enhances wound repair and improves tissue regeneration, making it suitable for non-invasive facial rejuvenation (nasolabial folds, crow’s feet, forehead lines) and body areas with laxity (neck, elbows, knees) while maintaining a natural look without volumising filler effects.

Bnefits

  • 100% human-identical recombinant collagen (Type I + Type III) for high biocompatibility and minimal immune reaction.
  • Dual collagen action: Type I collagen provides immediate structural scaffolding and lifting; Type III collagen supports long-term regeneration and dermal remodelling.
  • Enhanced formulation including hyaluronic acid for hydration, PDRN for tissue repair, succinic acid for fibroblast activation and multi-peptides for firming and wrinkle reduction.
  • Clinically reported superior wound repair efficacy (around 78% within 24 hours) compared with animal-derived collagen (around 57%).
  • Increases tissue regeneration (reported improvement of about 52.8%) and fibroblast activity (around 15–19% higher cell activity than animal collagen).
  • Improves skin firmness, elasticity and texture while reducing fine lines and wrinkles in face, neck and body areas.
  • Provides visible lifting and tightening with progressive improvement over weeks as new collagen and elastin are synthesised.
  • Animal-free recombinant technology, reducing risks associated with animal-derived collagen and supporting ethical, sustainable sourcing.
  • Can be combined with other aesthetic modalities (RF microneedling, lasers, mesotherapy, LED, etc.) for synergistic regenerative effects.
  • Designed for natural-looking rejuvenation rather than volumetric filling, maintaining facial expression and contours.

Indications

  • Non-surgical facial rejuvenation and dermal regeneration.
  • Static and dynamic wrinkles such as nasolabial folds, marionette lines, crow’s feet and forehead lines.
  • Skin laxity and textural changes of the midface, jawline and lower face.
  • Neck and décolletage wrinkles and crepey skin.
  • Hand, elbow and knee rejuvenation where skin laxity and thinning are present.
  • Patients seeking regenerative, collagen-stimulating treatment without classic hyaluronic acid filler volumisation.
  • Adjunctive treatment to support wound repair, post-procedure recovery and overall dermal quality (within professional protocols).

Composition

  • Recombinant human Type I collagen – 7.5 mg (human-identical sequence).
  • Recombinant human Type III collagen – 7.5 mg (human-identical sequence).
  • Hyaluronic acid (HA) – non-crosslinked hydrating polymer (exact concentration not publicly specified).
  • PDRN (polynucleotide) – DNA fragments supporting tissue repair and cellular metabolism.
  • Succinic acid – dicarboxylic acid associated with fibroblast activation and antioxidant effects.
  • Multi-peptides – bioactive peptides targeting skin firming, anti-wrinkle activity and cellular signalling.
  • Buffered aqueous excipients and stabilisers suitable for injectable use (exact formulation proprietary).

Formulation

  • Sterile, injectable recombinant human collagen gel/solution for intradermal or subdermal administration.
  • Combination of recombinant human Type I and Type III collagen with HA, PDRN, succinic acid and peptides.
  • Human-identical collagen produced via recombinant DNA technology in a controlled laboratory environment.
  • Animal-free, high-purity formulation designed to integrate into dermal tissue and stimulate endogenous collagen production.

Packaging

  • 1 x 2.5 mL pre-filled sterile syringe per box.
  • Supplied as a single-use injectable device for professional use only.
  • Outer carton with product labelling, batch number and expiry date.
  • Accompanied by instructions for use and professional handling guidelines.

Usage

  • For professional aesthetic use only by appropriately trained and licensed practitioners.
  • Assess patient’s medical history, indications, contraindications and expectations; obtain informed consent.
  • Clean and disinfect the treatment area following standard aseptic protocol.
  • Recommended injection depth: intradermal or superficial/sub-dermal depending on indication and technique.
  • Common devices and techniques include 27G needle (e.g. 27G 13 mm) or 25–27G cannula using retrograde linear threading, fanning or micro-depot technique according to treatment plan.
  • Typical initial protocol: two treatment sessions spaced approximately 4–6 weeks apart, targeting areas such as nasolabial folds, cheeks, periocular region, forehead, neck or body zones with laxity.
  • Maintenance protocol (example from clinical use): repeat a 2-session course every 3–4 months, or as clinically indicated, to sustain collagen stimulation and results.
  • Post-treatment care: avoid excessive pressure, massage or trauma to the area for a specified period; advise patients to avoid extreme temperatures, saunas and vigorous exercise immediately after treatment per clinic protocol.
  • Monitor for expected immediate responses (mild swelling, erythema, tenderness) and instruct the patient on when to seek medical attention if unusual or severe reactions occur.
  • Do not reuse any remaining product; PURI COLL Rh syringes are single-use only and should be disposed of as sharps/clinical waste.

Contraindications

  • Known hypersensitivity or allergy to recombinant human collagen, hyaluronic acid, PDRN, succinic acid, peptides or any excipients in the formulation.
  • Active skin infection, inflammation or dermatologic disease at or near the intended injection site (e.g. herpes, bacterial infection, dermatitis).
  • Systemic infection, fever or acute illness at the time of treatment.
  • History of severe keloid or hypertrophic scarring in the proposed treatment area (use with caution or avoid).
  • Autoimmune connective tissue disorders or immunosuppression where injectable collagen stimulators are contraindicated, unless under specialist supervision.
  • Pregnancy and breastfeeding, unless the treating physician determines that treatment is appropriate (commonly considered a precaution/relative contraindication in aesthetics).
  • Use in patients under the minimum legal/ethical age for aesthetic procedures according to local regulations.

Adverse Effects

  • Common, usually transient injection-site reactions: redness, swelling, tenderness, warmth, itching, bruising or mild pain.
  • Temporary nodules, lumps or irregularities at injection sites, especially if product placement is uneven or post-care instructions are not followed.
  • Less common but possible: inflammatory reactions, prolonged oedema, hyperpigmentation in predisposed individuals or flare of underlying skin conditions.
  • Rare but serious: infection, abscess, vascular compromise/occlusion if injected intravascularly, or severe inflammatory or immune-mediated responses.
  • As with any injectable aesthetic treatment, improper technique may increase the risk of complications; appropriate training, asepsis and anatomical knowledge are essential.

Storage Conditions

  • Store in a refrigerator at 2–8 °C.
  • Do not freeze; freezing may damage the collagen structure and compromise product performance.
  • Keep in original packaging, protected from direct light and excessive heat.
  • Do not use after the expiry date printed on the packaging.
  • Once removed from refrigerated storage, handle according to manufacturer instructions and return unused, unopened units to 2–8 °C promptly.
  • Single-use syringe; discard any unused product after opening in accordance with local regulations for clinical sharps and medical waste.

Duration

Initial course commonly consists of 2 sessions approximately 4\u20136 weeks apart, with maintenance courses (often 2 sessions) every 3\u20134 months depending on skin condition and clinical goals. Clinical improvements in skin texture, firmness and elasticity typically develop progressively over several weeks to months after each course, with longevity influenced by patient age, lifestyle and baseline skin quality.

Onset

Some immediate lifting and tightening may be visible directly after treatment due to the physical collagen scaffold, with early improvement in skin texture and fine lines developing within days to a few weeks. More pronounced collagen remodelling and elasticity improvements usually become evident over 4\u201312 weeks as fibroblast activity and new collagen/elastin synthesis progress.

Browse more Injectable skin booster

Top Treatments

Top Cities in the UK